Comparing the current results to its competitors, Capricor Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.21 %, recorded in the same quarter.
Capricor Therapeutics inc , slower than the average decrease reported by the company's competitors of -61.6 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -61.6 %
Capricor Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment alongside established pharmaceutical companies and biotechnology firms developing vaccines and biologics for infectious diseases such as SARS-CoV-2. Competition extends to other technological areas, including exosome-based vaccines and therapeutics. The biotechnology and pharmaceutical industries experience rapid technological changes, with product candidates competing on factors such as efficacy, safety, time to market, price, side-effect profile, and ease of administration. Additionally, companies developing alternative technologies compete for clinical trial participants, qualified personnel, and potential collaborators or strategic partners. The U.S. Food and Drug Administration (FDA) regulates drugs extensively, including granting orphan drug designation, which can provide exclusivity and potentially restrict approval of similar therapeutic candidates by competitors.
September 9, 2025
Investors on Alert: Capricor Therapeutics Faces Class Action Amid Declining Revenue and Controversial Phase 2 Trial DataIn a significant development for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), a class action lawsuit has been filed against the company, sparking concern over its handling of critical trial data and financial performance. Investors are urged to be vigilant, as the deadline to file as a lead plaintiff in this case is looming September 15, 2025. Holzer and Holzer, LLC, the firm spearheading the lawsuit, encourages those with substantial losses due to Capricor’s alleged misrepresentations to come forward.The lawsuit asserts that Capricor made materially misleading statements ...
August 21, 2025
In the ever-shifting landscape of healthcare investment, few stories encapsulate both the promise and peril of biotech ventures quite like that of Capricor Therapeutics, Inc. Following a recent announcement from Bronstein, Gewirtz and Grossman LLC, investors who feel the sting of substantial losses now find themselves at a crossroads and a chance for reclamation may be on the horizon.On August 21, 2025, the acclaimed law firm informed shareholders that a class action lawsuit has been filed against Capricor Therapeutics, a company whose innovations in regenerative medicine have sparked considerable hope among patients and investors alike. With 45.7 million shares outstanding and a current trading price of $...
January 2, 2025
Pioneering Progress: Capricor Therapeutics Advances Toward Approval of Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy Capricor Therapeutics, a biopharmaceutical company at the forefront of regenerative medicine, has made significant strides in its pursuit of innovative treatments for Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. With the completion of its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for Deramiocel, the company positions itself as a potential leader in transforming the landscape of DMD treatment. The approval of Deramiocel would mark a historical milestone as the first therapy...
June 28, 2024
In recent announcements, Capricor Therapeutics shares exciting developments regarding their experimental therapy, CAP-1002, for the treatment of Duchenne Muscular Dystrophy (DMD). The company reports positive outcomes in a long-term study, dubbed HOPE-2 OLE, indicating potential benefits for both skeletal muscle and cardiac function in DMD patients. Additionally, the analysis of the Performance of the Upper Limb (PUL v2.0) assessment reveals a slowdown in disease progression among later-stage DMD patients. These findings are remarkably significant, further reinforcing the potential efficacy of CAP-1002 in DMD management and providing hope for patients and their families.Capricor Therapeutics recently release...
May 9, 2024
Capricor Therapeutics, a pioneering biotechnology firm, is on the verge of revolutionizing medical science with its continuous developments in exosome platform technology, robust manufacturing processes, and strategic collaborations. In the recent American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, the firm presented notable updates on its innovative and robust exosome platform.The company highlighted promising preclinical findings that underscore the potential of an exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D). This is a significant breakthrough that might provide a new glimmer of hope for patients with this rare, life-threatening metabolic diseas...
April 24, 2024
aims to provide readers with unbiased and factual information regarding the latest advancements in pharmaceutical research and development. In line with this , this article discusses the recent positive feedback received by Capricor Therapeutics from the U.S. Food and Drug Administration (FDA) during a Type-B meeting for their CAP-1002 program designed to address Duchenne Muscular Dystrophy (DMD).Background:DMD is a severe genetic disorder primarily affecting males, characterized by the progressive degeneration of skeletal and cardiac muscles. Capricor Therapeutics, a California-based biotechnology company, has been developing CAP-1002, a cell-based investigational therapy, to address the unmet medical nee...
January 24, 2024
Capricor Therapeutics Collaborates with National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2In recent months, the world has witnessed an unparalleled scientific effort to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19. Although multiple vaccines have been authorized for emergency use, the need for innovative and effective solutions remains high. Capricor Therapeutics, a leading developer of biological therapies, has embarked on an exciting venture that holds promise for the future of COVID-19 prevention. Their collaboration with the National Institutes of Health (NIH) for a clinical trial of a novel exosome-ba...
Publicly Traded Peers of Capricor Therapeutics inc
Mesabi Trust Share Performance
-9.16%
This Quarter
Mesabi Trust
Profile
Mesabi Trust operates as a royalty trust, collecting royalty interest from leases of iron ore properties in Minnesota, United States. The trust receives revenue based on the mining and production of iron ore by others and distributes the collected amount to its unitholders on a quarterly basis. Essentially, Mesabi Trust's business model relies on generating income through the leasing and extraction of iron ore resources.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.
Moleculin Biotech Inc is a biopharmaceutical company that develops innovative cancer therapies by targeting key enzymes and signaling pathways involved in the progression of tumors. Their business model revolves around conducting preclinical and clinical trials to advance their drug candidates, with a focus on maximizing therapeutic impact and commercial potential.
Larimar Therapeutics Inc's business model revolves around the development and commercialization of innovative therapeutics for the treatment of rare and serious genetic diseases.
Sources:
Capricor Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Capricor Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
